Bioventus Inc. (BVS) SEC Filings & Earnings Calls

Surgical Solutions revenue declined 4.5% due to challenging comp and timing shifts; Restorative Therapies down 2.4% due to Medicare mix.

“Surgical Solutions: Global revenue of $50.4 million decreased 4.5%; Restorative Therapies: Global revenue of $21.1 million decreased 2.4% due to a change in customer mix, specifically with Medicare patients” · word for word

Strategic alternatives review uncertainty

“In August 2026, the Company announced that a committee of independent directors of the Board of Directors of the Company is engaged in a review of potential strategic alternatives aimed at maximizing value for the Company's stockholders following the receipt of an unsolicited acquisition proposal and other unsolicited indications of interest.” · word for word

Surgical Solutions and Restorative Therapies decline

“Net sales from Surgical Solutions decreased $2.2 million compared to the prior year, primarily due to lower Ultrasonics volumes, while net sales from Restorative Therapies decreased $0.4 million compared to the prior year due to an unfavorable customer mix for our EXOGEN Bone Stimulation System.” · word for word

Potential future CMS actions could materially impact Exogen reimbursement and financial outlook.

“Potential further changes by CMS to the applicable Medicare reimbursement rates for the Exogen device could require the Company to revise its financial outlook.” · word for word

Revenue growth partially driven by one-time favorable rebate benefit from billing process change.

“Pain Treatments increase primarily due to a $4.2 million favorable rebate benefit related to a billing process change implemented by a third-party private insurance payer”

HA Volume Decline

“This increase was partially offset by a 1.7% decline in HA volume.” · word for word

Rebate Adjustment Uncertainty

“The rebate claims reflected in these billings were at the low end of our estimated range of possible outcomes.” · word for word

Reported revenue decline due to prior-year divestiture of Advanced Rehabilitation Business.

“Full-year 2025 worldwide revenue totaled $568.1 million, a decrease of 0.9% compared to the prior-year period due to the divestiture of the Advanced Rehabilitation Business.” · word for word

Medicare Part B reimbursement reform

“The Proposed Rule includes significant proposed changes to CMS’s definition of bona fide service fees (“BFSFs”) for purposes of average sales price (“ASP”) calculations, which is the metric used to determine reimbursement under Medicare Part B.” · word for word

Payer rebate volume increase

“A large private insurance payer recently informed us that it has made changes to its claims data management and billing systems and that, as a result, we expect that we may experience significantly larger rebate volumes for our HA viscosupplement products for future periods than the Company previously estimated or has experienced in prior periods.” · word for word